Potti Anil, Nevins Joseph R
Duke Institute for Genome Sciences and Policy, Duke University Medical Center, Durham, NC 27708, United States.
Curr Opin Genet Dev. 2008 Feb;18(1):62-7. doi: 10.1016/j.gde.2008.01.018. Epub 2008 Mar 12.
The success of treatment of cancer patients depends on matching the most effective therapeutic regimen with the characteristics of the individual patient, balancing benefit against risk of adverse events. The primary challenge in achieving this goal is the heterogeneity of the disease, recognizing that breast, lung, colon and other cancers are not single diseases but rather an array of disorders with distinct molecular mechanisms. Genomic analyses, and in particular gene expression profiling, has been shown to have the capacity to dissect this heterogeneity and afford opportunities to match therapies with the characteristics of the individual patient's tumor. Here we review the success in developing gene expression signatures that have the capability of predicting response to various commonly used and newly developing cancer therapeutics. We further discuss the challenges and the opportunities in utilizing these tools in present-day clinical practice.
癌症患者的治疗成功取决于将最有效的治疗方案与个体患者的特征相匹配，权衡获益与不良事件风险。实现这一目标的主要挑战在于疾病的异质性，要认识到乳腺癌、肺癌、结肠癌及其他癌症并非单一疾病，而是一系列具有不同分子机制的病症。基因组分析，尤其是基因表达谱分析，已被证明有能力剖析这种异质性，并为使治疗方案与个体患者肿瘤的特征相匹配提供机会。在此，我们回顾在开发具有预测对各种常用和新开发癌症治疗药物反应能力的基因表达特征方面所取得的成功。我们还将进一步讨论在当今临床实践中使用这些工具所面临的挑战和机遇。
